Recent studies suggest that angiotensin II (Ang II) has a role in the development of prostate cancer and drugs that inhibit Ang II type I (AT1-) or stimulate Ang II type 2 (AT2-) receptors may modulate the mitogenic effects of Ang II and EGF in prostate cancer [1-4]. Here, AGTR2 is linked to prostate cancer.